# An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials.

> PubMed lists PMID 23384406 in Neurogastroenterology and motility as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-02-06 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-23384406-linaclotide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-23384406-linaclotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-23384406-linaclotide-v1.json
- Content SHA-256: `be4ef46bae5e8c6e4d7236835d7782d08ecd6da068a3b0d19907f377bdd8fade`

## Claims and source pins

### Headline

An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. ([`pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e`](#source-pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e))

### Summary

PubMed lists PMID 23384406 in Neurogastroenterology and motility as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-02-06 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e`](#source-pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e))

### Paragraph 1

PubMed lists PMID 23384406 in Neurogastroenterology and motility as Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-02-06 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e`](#source-pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e`](#source-pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e))

## Sources

<a id="source-pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e"></a>
- **An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials. · retained source version 1:2026-01-28:current:f13eb769169ecaff2e102ebff7f8baae47ad35356ae50f4223e8fdfd256c15b5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/23384406/) (`pubmed-observation-pmid-23384406-2026-01-28-f13eb769169e`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "An evaluation of the FDA responder endpoint for IBS-C clinical trials: analysis of data from linaclotide Phase 3 clinical trials." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-23384406-linaclotide-v1.json SHA-256: be4ef46bae5e8c6e4d7236835d7782d08ecd6da068a3b0d19907f377bdd8fade.